This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The purpose was to assess the cost-effectiveness of the addition of one year of adjuvant trastuzumab therapy after adjuvant chemotherapy in women with early breast cancer.
Interventions
The four strategies were compared with strategy one, which was the standard care and consisted of no testing and no adjuvant trastuzumab therapy.
Strategy two was immunohistochemical (IHC) test followed by one year of adjuvant trastuzumab for those patients with a IHC +3 result and standard care for all other patients.
Strategy three was IHC test followed by one year of adjuvant trastuzumab for patients with IHC +2 and +3 results and standard care for all other patients.
Strategy four was IHC test followed by fluorescence in-situ hybridisation (FISH) test confirmation for patients with IHC +2 and +3 results followed by one year of adjuvant trastuzumab for FISH positive patients and standard care for all other patients.
Strategy five was FISH test followed by one year of adjuvant trastuzumab for FISH positive patients and standard care for all other patients.
Trastuzumab was administered using an 8mg/kg loading dose, followed by 6mg/kg every third week for a total of 17 doses. Women in the hypothetical cohort were assumed to have completely excised the breast cancer, completed at least four cycles of adjuvant chemotherapy, and were aged 55 years.
Location/setting
Sweden/secondary care.
Methods

Analytical approach:
A Markov model was developed using published sources to compare the alternative strategies over a lifetime. The authors stated that a societal perspective was adopted, in a Swedish setting.
